PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Gettinger, 2015, Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A, J Clin Oncol, 33, 3015, 10.1200/jco.2015.33.15_suppl.3015 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, 16, 257, 10.1016/S1470-2045(15)70054-9 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Rizvi, 2015, Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8032, 10.1200/jco.2015.33.15_suppl.8032 Spigel, 2015, Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 8028, 10.1200/jco.2015.33.15_suppl.8028 Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Merck and Company, Inc. FDA approves Merck's KEYTRUDA (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK genomic tumor aberrations. http://wwwmercknewsroomcom/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-metastatic-nsclc-. Accessed November 10, 2016. U.S. Food and Drug Administration. Nivolumab (Obdivo). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm. Accessed November 10, 2016. U.S. Food and Drug Administration. FDA approves Keytruda for advanced non-small cell lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm. Accessed November 10, 2016. Roche: Media release: Roche receives FDA approval for novel PD-L1 biomarker assay. http://www.ventana.com/pd-l1-biomarker-assay-news. Accessed November 10, 2016. Dako PD-L1 IHC 28-8 pharmDX IFU. http://www.agilent.com/en-us/products/pharmdx/pd-l1-ihc-28-8-overview. Accessed November 10, 2016. Dako PD-L1 IHC Pharm testing. http://www.agilent.com/en-us/products/pharmdx/pd-l1-ihc-22c3-pharmdx-testing. Accessed November 10, 2016. Kerr, 2015, Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?, J Thorac Oncol, 10, 985, 10.1097/JTO.0000000000000526 Cagle, 2015, Challenges to biomarker testing for PD-1/PD-L1 checkpoint inhibitors for lung cancer, Arch Pathol Lab Med, 139, 1477, 10.5858/arpa.2015-0902-ED Kerr, 2016, Programmed death ligand-1 immunohistochemistry: friend or foe?, Arch Pathol Lab Med, 140, 326, 10.5858/arpa.2015-0522-SA U.S. Food and Drug Administration. A blueprint proposal for companion diagnostic comparability. http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM439440.pdf. Accessed November 10, 2016. Phillips, 2015, Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer, Appl Immunohistochem Mol Morphol, 23, 541, 10.1097/PAI.0000000000000256 Roach, 2016, Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer, Appl Immunohistochem Mol Morphol, 24, 392, 10.1097/PAI.0000000000000408 Rebelatto, 2016, Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma, Diagn Pathol, 11, 95, 10.1186/s13000-016-0545-8 Ilie, 2016, Comparative study of the PD-L1 status between surgically resectedspecimens and matched biopsied of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann Oncol, 27, 147, 10.1093/annonc/mdv489 Scheel, 2016, Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod Pathol, 29, 1165, 10.1038/modpathol.2016.117 Ruschoff, 2013, Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test, Arch Pathol Lab Med, 137, 1255, 10.5858/arpa.2012-0605-OA Fitzgibbons, 2014, Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center, Arch Pathol Lab Med, 138, 1432, 10.5858/arpa.2013-0610-CP Lin, 2014, Standardization of diagnostic immunohistochemistry: literature review and geisinger experience, Arch Pathol Lab Med, 138, 1564, 10.5858/arpa.2014-0074-RA Dolled-Filhart, 2015, Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC), J Clin Oncol, 33, 11065, 10.1200/jco.2015.33.15_suppl.11065 Rebelatto, 2015, Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients, J Clin Oncol, 33, 8033, 10.1200/jco.2015.33.15_suppl.8033 Neuman, 2016, A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana's platform, J Thorac Oncol, 11, 1863, 10.1016/j.jtho.2016.08.146 Ibrahim, 2016, ALK Immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen, J Thorac Oncol, 11, 2241, 10.1016/j.jtho.2016.07.012 Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathology Lab Med, 131, 18, 10.5858/2007-131-18-ASOCCO Patel, 2015, PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, 14, 847, 10.1158/1535-7163.MCT-14-0983